Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EPS (Weighted Average and Diluted) (2020 - 2026)

Fulcrum Therapeutics (FULC) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.31 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 14.81% to -$0.31 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.18 through Dec 2025, down 555.56% year-over-year, with the annual reading at -$1.18 for FY2025, 637.5% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.31 at Fulcrum Therapeutics, roughly flat from -$0.31 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.87 in Q2 2024, with the low at -$0.83 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.38, with a median of -$0.4 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 328.95% in 2024, then plummeted 132.18% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.58 in 2021, then increased by 18.97% to -$0.47 in 2022, then increased by 14.89% to -$0.4 in 2023, then skyrocketed by 32.5% to -$0.27 in 2024, then dropped by 14.81% to -$0.31 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.31, -$0.31, and -$0.28 for Q4 2025, Q3 2025, and Q2 2025 respectively.